Gipid 1mg

Tablet
Glimepiride
Alco Pharma

Other Strength:
- Gipid 2mg

Alternative:
- DACTUS 1mg
- Secrin 1mg
- Limaryl 1mg
- Glimirid 1mg
- Adglim 1mg
- Gluconor 1mg



Gipid
Description:
Glimepiride is an oral blood glucose lowering drug of the sulfonylurea class.

Pharmacology:
The primary mechanism of action of Glimepiride appears to be dependent on stimulating the release of insulin from functioning pancreatic beta-cells. Glimepiride acts in concert with glucose by improving the sensitivity of beta-cells to physiological glucose stimulus, resulting in insulin secretion. In addition, extra pancreatic effects like reduction of basal hepatic glucose production, increased peripheral tissue sensitivity to insulin and glucose uptake may also play role in the activity of Glimepiride.

Indication/Use:
Gipid (Glimepiride) is indicated as an adjunct to diet and exercise to lower the blood glucose in patients with Non Insulin Dependent (Type-2) Diabetes Mellitus (NIDDM) whose hyperglycemia can’t be controlled by diet and exercise alone. Gipid (Glimepiride) may be used concomitantly with metformin when Glimepiride or metformin alone does not result in adequate glycaemic control. Gipid (Glimepiride) is also indicated for use in combination with insulin to lower blood glucose in patients whose hyperglycemia can’t be controlled by diet and exercise in conjunction with an oral hypoglycaemic agent. Combined use of Glimepiride and insulin may increase the potential for hypoglycemia.

Dosage Guideline:
There is no fixed dosage regimen for the management of diabetes mellitus with Gipid or any other hypoglycemic agent. The initial and the maintenance dosage are set based on the results of regular check of glucose in blood and urine.

Usual starting dose: The usual starting dose of Gipid as initial therapy is 1 to 2 mg once daily, administered with breakfast or the first main meal. Those patients who may be more sensitive to hypoglycemic agents should be started with 1 mg once daily and should be titrated carefully. There is no exact dosage relationship between Gipid and other oral blood glucose lowering agents. The maximum starting dose of Gipid should be no more than 2 mg.
Usual maintenance dose: The usual maintenance dose is 1 to 4 mg once daily. The maximum recommended dose is 8 mg once daily. After reaching of a dose of 2 mg, dosage increases should be made in increments of no more than 2 mg at 1 to 2 weeks intervals based upon the patient's blood glucose response.
Patients receiving other oral hypoglycemic agents: As with other sulfonylurea hypoglycemic agents, no transition period is necessary when transferring patients to Gipid. Patients should be observed carefully (1 to 2 weeks) for hypoglycemia when being transferred from longer-half life sulfonylureas (e.g. chlorpropamide) to Gipid due to potential overlapping of drug effect.

Administration:
Glimepiride tablets must be swallowed without chewing and with sufficient amounts of liquid (approximately one or two glass).

Side Effects:
Hypoglycemia may occur. Other side effeects are nausea, vomiting, gastrointestinal pain, diarrhea, dizziness, weakness and headache. Dermatologic Reactions: Allergic skin reactions, e.g., pruritus, erythema, urticaria and morbilliform or maculopapular eruptions, occur in less than 1% of treated patients. These may be transient and may disappear despite continued use of glimepiride.

Contraindication:
Glimepiride is contraindicated in patients with-
Known hypersensitivity to the drug.
Diabetic ketoacidosis, with or without coma. This condition should be treated with insulin.

Drug Interaction:
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs, including NSAIDs and other drugs that are highly protein bound, such as salicylates, sulfonamides, chloramphenicol, coumarins, probenecid, MAO inhibitors and beta adrenergic blocking agents. Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics and isoniazid.

Use in Pregnancy & Lactation:
Pregnancy: Glimepiride must not be taken during pregnancy. Patients planning a pregnancy must inform their physician and should changeover to insulin.
Lactation: Ingestion of Glimepiride with breast milk feeding may harm the child. Therefore, Glimepiride must not be taken by breast-feeding women. Either a changeover or a complete discontinuation of breast-feeding is necessary.

Over Dose:
Overdose of glimepiride can produce hypoglycemia. Mild hypoglycemic symptoms without loss of consciousness or neurologic findings should be treated aggressively with oral glucose and adjustments in drug dosage and/or meal patterns. Close monitoring should continue until the physician is assured that the patient is out of danger.

Precaution:
Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when alcohol is ingested or when more than one glucose-lowering drug is used. Combined use of glimepiride with insulin or metformin may increase the potential for hypoglycemia.

Therapeutic Class:
Antidiabetic

Dosage Form:
Tablet

Storage:
Store in a cool, dry place & away from light. Keep medicines out of reach of children.


এই পাতাটি ২৯৮ বার দেখা হয়েছে